CJC-1295 DAC

Product Description CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH). It features a modified 30-amino acid sequence with a DAC moiety that extends its half-life through albumin binding. Supplied as ≥98% pure lyophilized powder (HPLC/MS verified), it is designed for laboratory studies on growth hormone secretion, IGF-1 regulation, and related endocrine pathways.

Key Research Mechanism CJC-1295 with DAC acts as a GHRH receptor agonist in the pituitary gland, stimulating sustained release of growth hormone (GH). The DAC component prolongs its activity (half-life ~6-8 days), leading to elevated GH and IGF-1 levels for extended periods in research models.

Primary Research Areas

• Growth hormone & IGF-1 axis studies (sustained elevation in preclinical and clinical models)
• Body composition and metabolism research (muscle growth, fat reduction)
• Endocrine regulation and pituitary function
• Anti-aging, recovery, and regenerative biology models

Intended Use For in vitro and in vivo research only. Not for human or veterinary use. This product is sold strictly for scientific and laboratory investigation. Researchers must follow all institutional and regulatory guidelines. Not evaluated by the FDA.